Chardan Capital Markets Downgrades NeuBase Therapeutics (NBSE) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. NVDA
2. PCVX
3. PTC
4. MSFT
5. SPY
6. META
7. GOOGL
8. GMAB
9. AMD
10. BBIO

Go back to Chardan Capital Markets Downgrades NeuBase Therapeutics (NBSE) to Neutral

NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing

October 14, 2022 4:05 PM EDT

Workforce reductions of ~60% and implementation of a robust cost reduction plan are expected to extend the Companys cash runway into Q2 CY2024The Company plans to maximize shareholder value by focusing R&D resources on advancement of the differentiated gene editing capabilities of the Companys platform Company to reduce activities and pursue partnerships for myotonic dystrophy type 1 (DM1), Huntingtons disease (HD), and KRAS (G12D & G12V) programsDov A. Goldstein,... More